Outcome of anthracycline-related cardiomyopathy – experience of a cardiooncology clinic at a tertiary referral cancer centre
Languages of publication
Introduction: The most common form of cardiotoxicity in cancer treatment is anthracycline-related cardiomyopathy. Objective: To study the factors affecting response to heart failure (HF) therapy in patients with anthracycline- related cardiomyopathy (ARC). Methods: Patients with ARC were included in the study. ARC was defined as left ventricular ejection fraction (LVEF) < 50% in patients who had received anthracycline based chemotherapy. 2Decho was done at baseline and every 3 months after starting anti-heart failure treatment. The primary endpoint of the study was response to anti-heart failure treatment. The patients were considered as responders when LVEF increased at least 10 absolute points. The secondary endpoint was overall survival. Results: 177 patients with ARC were included in the study. The median cumulative dose of doxorubicin was 275 mg/m2. Median clinical follow up duration was 19 months (range 3–73 months). 55% were responders. 25 cumulative doxorubicin dose of more than 200 mg/m2 increased the likelihood of non-response (p = 0.008), by a factor of 3.07 (95% CI: 1.34–7.05). 25 patients expired. There was a significant difference in overall survival among responders as compared to non-responders (p value: 0.002, log rank test). Conclusions: In patients with ARC cumulative doxorubicin dose of more than 200 mg/m2 increased the likelihood of non-response to anti-heart failure treatment. Responders have a better overall survival compared to non-responders in patients with ARC.
- 1. Allemani C, Weir HK, Carreira H et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385 (2015): 977-1010.
- 2. Felker GM et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 2000; 342: 1077- 1084.
- 3. Mertens AC, Yasui Y, Neglia JP et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J. Clin. Oncol. 2001; 19(13): 3163-3172.
- 4. Schultz PN, Beck ML, Stava C et al. Health profiles in 5836 long-term cancer survivors. Int J Cancer 2003; 104(4): 488-495.
- 5. Steinherz LJ, Steinherz PG, Tan CT et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672–1677.
- 6. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines Annals of Oncology 2010; 21(supplement 5): v277-v282.
- 7. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol 2010; 7: 564-575.
- 8. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.
- 9. Khorana AA, Francis CW, Culakova E et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632.
- 10. Lestuzzi C. Neoplastic pericardial disease: old and current strategies for diagnosis and management. World J cardiol. 2010; 2: 270-279.
- 11. Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxidefor acute promyelocytic leukemia. Ann Intern Med 2001; 135: 842-843.
- 12. López Medrano F, Sánchez Munoz A, Sánchez Sánchez V et al. Cardiotoxicity of 5-fluorouracil: ischemia or myocardial toxicity? Rev Clin Esp 2001; 201: 106-107.
- 13. Galper SL, Yu JB, Mauch PM et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117(2): 412-419.
- 14. Gianni L, Herman EH, Lipshultz SE et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008; 26: 3777-3784.
- 15. Raschi E, Vasina V, Ursino MG et al. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 2010; 125: 196-218.
- 16. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
- 17. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
- 18. Blanco JG, Sun CL, Landier W et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children’s Oncology Group. J Clin Oncol: Off J Am Soc Clin Oncol 2012; 30(13): 1415-1421.
- 19. Russell SD, Blackwell KL, Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. Journal of clinical oncology official journal of the American Society of Clinical Oncology 2010; 28(21): 3416-3421.
- 20. Curigliano G, Cardinale D, Suter T et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Annals of Oncology 2012; 23(supplement 7): vii155–vii166.
- 21. Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(36): 2768.
- 22. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002 May; 13(5): 699-709.
- 23. Watts RG, George M, Johnson WH: Jr Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: A 5-year review at a single pediatric oncology center. Cancer 2012; 118: 1919-1924.
- 24. Fallah-Rad N, Walker JR, Wassef A et al. The utility of cardiac biomarkers, tissue velocity and strain imaging and cardiac MRI in predicting early left ventricular dysfunction in patients with HER-2 positive breast cancer treated with adjuvant Trastuzumab therapy. J Am Coll Cardiol 2011; 57: 2263- -2270.
- 25. Sawaya H, Sebag IA, Plana JC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596-603.
- 26. Thavendiranathan P, Poulin F, Lim KD et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014; 63: 2751-2768.
- 27. Cardinale D, Sandri MT, Martinoni A et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13: 710-715.
- 28. Cardinale D, Colombo A, Lamantia G. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55(3): 213-220.
- 29. Cardinale D, Colombo A, Bacchiani G et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131(22): 1981-1988.
Publication order reference